Health ❯ Nutrition ❯ Weight Management ❯ Pharmaceuticals

Clinical Trials

Novo Nordisk Extends Weight‑Loss Lead as Amgen’s Once‑Monthly MariTide Reaches Phase 3

Investors gauge Novo’s broader pipeline versus Amgen’s dosing convenience.

FDA Approves First Oral GLP-1 for Obesity as Novo’s Wegovy Pill Sets January U.S. Launch

Meta-Analysis Finds GLP-1 Drugs Show Little Short-Term Impact on Obesity-Linked Cancer Risk